Lumos Diagnostics Holdings Limited (LDX.AX)
ASX · AUD · Healthcare · Medical Devices
A$0.064 (-23.81%) as of
Key statistics
- Market cap
- 63.24M
- Forward P/E
- -4.53
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0640 – 0.3300
- Beta
- 0.46
- Revenue (TTM)
- 13.19M
- Profit margin
- -37.54%
- Analyst target
- A$0.30
- Volume
- 13.94M
About Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Carlsbad, CA, United States
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.